Fatty liver disease is becoming increasingly common around the world, especially as more people develop conditions such as obesity, diabetes, and metabolic syndrome.
While many people think of fatty liver as a mild condition, it can lead to serious health problems over time. One of the most concerning outcomes is liver cancer, which is one of the leading causes of cancer-related deaths globally.
A new study from researchers at the University of Hong Kong offers promising news. The team discovered that a drug already approved for treating fatty liver disease may also help prevent and slow down liver cancer.
The research was carried out by scientists from the LKS Faculty of Medicine at the University of Hong Kong, together with the HKU State Key Laboratory of Liver Research, and the findings were published in the journal Hepatology.
Liver cancer, also known as hepatocellular carcinoma, is the sixth most common cancer worldwide and the third leading cause of cancer-related death.
In recent years, more cases of liver cancer have been linked to metabolic problems rather than infections or alcohol use. This type of liver cancer is often connected to metabolic dysfunction-associated fatty liver disease, also known as MAFLD.
Studies suggest that around 3% of people with fatty liver disease may develop liver cancer each year. The burden is especially high in Asia, where a large portion of the population is affected by fatty liver.
Although treatments such as immunotherapy are available for advanced liver cancer, they do not always work well in patients whose cancer is linked to fatty liver. This has led scientists to search for new ways to understand and treat the disease.
In this study, the researchers used a mouse model that closely resembles human fatty liver disease. They applied advanced techniques to study changes in liver cells and immune cells during the development of cancer.
By analyzing a large number of individual cells, they were able to track how different types of cells interact and contribute to disease progression.
One key discovery was the role of a protein called Midkine, or MDK. The researchers found that MDK and its receptor form a pathway that promotes cancer growth. When MDK levels are high, it changes how the immune system behaves in the liver. Instead of fighting cancer, immune cells begin to support tumor growth.
For example, macrophages, which are usually responsible for cleaning up harmful substances, start to promote tumor development.
At the same time, T cells, which normally attack cancer cells, gradually lose their ability to function properly. This creates an environment where cancer cells can grow more easily and avoid being destroyed by the immune system.
The researchers also found that higher levels of MDK are linked to worse outcomes in patients with fatty liver-related liver cancer. People with higher MDK levels tend to have a greater risk of cancer returning and a shorter period without disease after treatment.
An important part of the study focused on a drug called Resmetirom. This drug has already been approved by the U.S. Food and Drug Administration for treating fatty liver disease. The researchers discovered that Resmetirom not only reduces liver fat and improves metabolic health, but also lowers MDK levels and slows tumor growth.
In their experiments, Resmetirom showed strong anti-cancer effects. When combined with drugs that block MDK, the results were even more powerful.
The combination helped improve liver function, reduce fat buildup, and suppress tumor growth more effectively than either treatment alone. It also improved the immune environment in the liver, making it less supportive of cancer.
These findings suggest that Resmetirom could be used not only to treat fatty liver disease but also to help prevent liver cancer in people who are at high risk. This is an important step forward, as it points to a “prevention-first” approach. Instead of waiting for cancer to develop, doctors may one day be able to reduce the risk by treating the underlying causes early.
However, the researchers emphasize that more work is needed before these findings can be applied in clinical practice. Future studies will need to confirm the results in larger groups of patients and explore how best to combine Resmetirom with other treatments, such as immunotherapy.
Overall, this study provides new insight into how fatty liver disease can lead to cancer and highlights a promising new strategy for prevention and treatment. By targeting both metabolic problems and cancer-related pathways, Resmetirom may offer a more comprehensive approach to liver health.
In conclusion, the research shows strong potential but is still at an early stage. The results from animal studies are encouraging, especially the discovery of the MDK pathway and its role in weakening the immune system.
However, it is important to confirm whether the same effects occur in humans. If future clinical trials are successful, this approach could change how doctors manage fatty liver disease and reduce the risk of liver cancer.
It also highlights the importance of early intervention and the need to treat metabolic conditions before they progress to more serious diseases.
If you care about liver health, please read studies about simple habit that could give you a healthy liver, and common diabetes drug that may reverse liver inflammation.
For more information about health, please see recent studies about simple blood test that could detect your risk of fatty liver disease, and results showing this green diet may strongly lower non-alcoholic fatty liver disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
